SMALL MOLECULE POTENTIATOR OF HORMONAL THERAPY FOR BREAST CANCER

• US 20080085874A1
• Filed: 08/27/2007
• Published: 04/10/2008
• Est. Priority Date: 08/28/2006
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Goldfine, Ira, Valentine, Cathleen, Hodges-Gallagher, Leslie, Kushner, Peter
• Application Number:
  US11/845,554
• Publication Number:
  US 20080085874A1
• Time in Patent Office: Days
• US Class Current: 514/177
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/41 having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present application demonstrates that HDAC inhibitors can be used in combination with hormonal therapy to treat and prevent estrogen receptor positive breast cancer. HDAC inhibitors can also be combined with IGF-1R inhibitors, mTOR inhibitors, and EGFR inhibitors to treat breast cancer, optionally in combination with hormonal therapy if indicated. Combinations of the compounds, with or without HDAC inhibitors, and with or without hormonal therapy, can also be used. The invention therefore provides methods of treatment and pharmaceutical compositions.

Claims

1. A method of treating estrogen receptor positive breast cancer, the method comprising the step of administering to a subject a therapeutically effective amount of an HDAC inhibitor in combination with a course of hormonal therapy, wherein the HDAC inhibitor is not valproic acid.

2. The method of claim 1, wherein the HDAC inhibitor is not carbamazepine.

3. The method of claim 1, wherein the hormonal therapy is selected from the group consisting of anti-estrogen therapy and estrogen ablation therapy.

4. The method of claim 3, wherein the estrogen ablation therapy is an aromatase inhibitor.

5. The method of claim 4, wherein the aromatase inhibitor is selected from the group consisting of exemestane, letrozole, and anastrozole.

6. The method of claim 1, wherein the hormonal therapy is an aromatase inhibitor which is administered to the subject in an amount insufficient to fully prevent production of estrogen.

7. The method of claim 3, wherein the anti-estrogen therapy is selected from the group consisting of tamoxifen, raloxifene, fulvestrant, and torimefene.

8. The method of claim 7, wherein the anti-estrogen therapy is tamoxifen.

9. The method of claim 8, wherein the dose of tamoxifen is from about 10 mg/day to about 40 mg/day.

10. The method of claim 7, wherein less than estrogen receptor-saturating amounts of fulvestrant are administered to the subject.

11. The method of claim 1, wherein the HDAC inhibitor is selected from the group consisting of carbamazepine, TSA and SAHA.

12. The method of claim 1, wherein the HDAC inhibitor is administered every day and the hormonal therapy is administered every day.

13. The method of claim 1, wherein the HDAC inhibitor is administered every other day and the hormonal therapy is administered every day.

14. The method of claim 1, wherein the HDAC inhibitor and the hormonal therapy are administered concurrently.

15. The method of claim 1, wherein the HDAC inhibitor and the hormonal therapy are administered separately.

16. The method of claim 3, wherein the HDAC inhibitor is carbamazepine and the estrogen ablation therapy is letrozole.

17. The method of claim 3, wherein the HDAC inhibitor is carbamazepine and the anti-estrogen therapy is selected from the group consisting of tamoxifen, raloxifene, fulvestrant, and torimefene.

18. The method of claim 3, wherein the HDAC inhibitor is selected from the group consisting of carbamazepine, SAHA and TSA and the anti-estrogen therapy is tamoxifen.

19. The method of claim 16, wherein the dose of carbamazepine is from about 200 mg/day to about 600 mg/day.

20. The method of claim 16, wherein the dose of letrozole is from about 1 mg/day to about 5 mg/day.

21. The method of claim 1, wherein the breast cancer is tamoxifen-resistant.

22. The method of claim 1, wherein the breast cancer overexpresses Her2/Neu.

23. The method of claim 1, wherein the subject has failed previous therapy.

24. The method of claim 1, wherein the cancer is recurring.

25. The method of claim 1, wherein the subject is post-menopausal.

26. The method of claim 1, wherein the subject is at risk for breast cancer.

27. The method of claim 1, wherein the subject has Stage 1, Stage 2, Stage 3, or Stage 4 cancer.

28. A pharmaceutical composition comprising a therapeutically effective amount of an HDAC inhibitor in combination with a therapeutically effective amount of a hormonal therapy compound, wherein the HDAC inhibitor is not valproic acid.

29. The composition of claim 28, wherein the HDAC inhibitor is not carbamazepine.

30. The composition of claim 28, wherein the hormonal therapy compound is selected from the group consisting of an anti-estrogen therapy compound and an estrogen ablation therapy compound.

31. The composition of claim 30, wherein the estrogen ablation therapy compound is an aromatase inhibitor.

32. The composition of claim 31, wherein the aromatase inhibitor is selected from the group consisting of exemestane, letrozole, and anastrozole.

33. The composition of claim 31, wherein the aromatase inhibitor is present in an amount insufficient to fully prevent production of estrogen.

34. The composition of claim 30, wherein the anti-estrogen therapy compound is selected from the group consisting of tamoxifen, raloxifene, fulvestrant, and torimefene.

35. The composition of claim 30, wherein the anti-estrogen therapy is tamoxifen.

36. The composition of claim 35, wherein the dose of tamoxifen is from about 10 mg/day to about 40 mg/day.

37. The composition of claim 34, comprising less than estrogen receptor-saturating amounts of fulvestrant.

38. The composition of claim 28, wherein the HDAC inhibitor is selected from the group consisting of carbamazepine, TSA, and SAHA.

39. The composition of claim 28, wherein the HDAC inhibitor is carbamazepine and the estrogen ablation therapy compound is letrozole.

40. The composition of claim 39, wherein the dose of carbamazepine is from about 200 mg/day to about 600 mg/day.

41. The composition of claim 39, wherein the dose of letrozole is from about 1 mg/day to about 5 mg/day.

42. The composition of claim 30, wherein the HDAC inhibitor is carbamazepine and the anti-estrogen therapy compound is selected from the group consisting of tamoxifen, raloxifene, fulvestrant, and torimefene.

43. The composition of claim 30, wherein the HDAC inhibitor is selected from the group consisting of carbamazepine, SAHA and TSA and the anti-estrogen therapy compound is tamoxifen.

44. The composition of claim 42, wherein the dose of tamoxifen is from about 10 mg/day to about 40 mg/day.

45. The composition of claim 28, wherein the composition is formulated for parenteral or oral administration.

46. A method of preventing estrogen receptor positive breast cancer, the method comprising the step of administering to a subject a therapeutically effective amount of an HDAC inhibitor in combination with a course of anti-estrogen therapy or estrogen ablation therapy.

47. The method of claim 46, wherein there is no attendant increase in the risk of uterine cancer when the anti-estrogen therapy is tamoxifen or raloxifen as compared to treatment with tamoxifen and raloxifene alone.

48. The method of claim 46, wherein the subject is in remission from breast cancer.

49. The method of claim 46, wherein the subject has previously undergone treatment.

50. The method of claim 46, wherein the breast cancer is prevented from progressing from DCIS.

51. The method of claim 46, wherein the breast cancer is prevented from progressing from atypical hyperplasia.

52. The method of claim 46, wherein the anti-estrogen therapy is selected from the group consisting of tamoxifen and raloxifene, and the HDAC inhibitor is selected from the group consisting of valproic acid, carbamazepine, TSA, and SAHA.

53. The method of claim 46, wherein the estrogen ablation therapy is selected from the group consisting of exemestane, letrozole, and anastrozole.

54. The method of claim 52, wherein the ratio of valproic acid to tamoxifen is from about 1 part valproic acid to from about 22.5 to about 180 parts tamoxifen.

55. The method of claim 46, wherein the subject has a genetic predisposition to breast cancer.

56. The method of claim 46, wherein the subject has undergone surgery to remove a primary tumor.

57. A method of treating breast cancer, the method comprising the step of administering to a subject a therapeutically effective amount of an HDAC inhibitor in combination with a therapeutically effective amount of at least one compound selected from the group consisting of an IGF-1R inhibitor, an mTOR inhibitor, and an EGFR inhibitor, wherein the HDAC inhibitor is not valproic acid when the compound is an EGFR inhibitor.

58. The method of claim 57, wherein the IGF-1R inhibitor is selected from the group consisting of picropodophyllin and EGCG.

59. The method of claim 57, wherein the mTOR inhibitor is selected from the group consisting of rapamycin and rapamycin derivatives.

60. The method of claim 57, wherein the EGFR inhibitor is gefitinib.

61. The method of claim 57, comprising the step of administering to a subject a therapeutically effective amount of an HDAC inhibitor in combination with a therapeutically effective amount of an IGF-1R inhibitor and an mTOR inhibitor.

62. The method of claim 61, wherein the breast cancer is estrogen receptor positive and the compounds are administered further in combination with a course of hormonal therapy.

63. A pharmaceutical composition comprising a therapeutically effective amount of an HDAC inhibitor in combination with a therapeutically effective amount of at least one compound selected from the group consisting of an IGF-1R inhibitor, an mTOR inhibitor, and an EGFR inhibitor, wherein the HDAC inhibitor is not valproic acid when the compound is an EGFR inhibitor.

64. The composition of claim 63, wherein the HDAC inhibitor is valproic acid.

65. The composition of claim 63, wherein the HDAC inhibitor is carbamazepine.

66. The composition of claim 63, wherein the HDAC inhibitor is valproic acid or carbamazepine and the IGF-1R inhibitor is picropodophyllin.

67. The composition of claim 63, wherein the HDAC inhibitor is valproic acid or carbamazepine and the EGFR inhibitor is gefitinib.

68. The composition of claim 63, wherein the HDAC inhibitor is valproic acid or carbamazepine and the mTOR inhibitor is rapamycin.

69. The composition of claim 63, wherein the HDAC inhibitor is valproic acid or carbamazepine and the mTOR inhibitor is rapamycin.

70. The composition of claim 63, comprising a therapeutically effective amount of an HDAC inhibitor in combination with a therapeutically effective amount of an IGF-1R inhibitor and an mTOR inhibitor.

71. The composition of claim 63 or 70, wherein the compositions further comprise compounds for hormonal therapy.

72. The composition of claim 71, wherein the HDAC inhibitor is valproic acid or carbamazepine, the IGF-1R inhibitor is EGCG, and the hormonal therapy is tamoxifen.

73. The composition of claim 72, wherein the dose of EGCG is from about 300 mg/day to about 800 mg/day.

74. A method of treating estrogen receptor positive breast cancer, the method comprising the step of administering to a subject a therapeutically effective amount of an HDAC inhibitor in combination with a course of hormonal therapy and one or more additional active ingredients effective to treat estrogen receptor positive breast cancer in the combination.

75. The method of claim 74, wherein the HDAC inhibitor is carbamazepine.

76. The method of claim 75, wherein the dose of carbamazepine is from about 200 mg/day to about 600 mg/day.

77. The method of claim 74, wherein the HDAC inhibitor is valproic acid.

78. The method of claim 77, wherein the dose of valproic acid is from about 300 to about 1000 micromolar in patient serum.

79. The method of claim 77, wherein the dose of valproic acid is from about 500 to about 1000 micromolar in patient serum.

80. The method of claim 74, wherein the one or more additional active ingredients are selected from the group consisting of an IGF-1R inhibitor, an mTOR inhibitor, and an EGFR inhibitor.

81. The method of claim 74, wherein the hormonal therapy is selected from the group consisting of tamoxifen, letrozole, and torimefene.

82. A pharmaceutical composition comprising a therapeutically effective amount of an HDAC inhibitor in combination with a therapeutically effective amount of a hormonal therapy compound and one or more additional active ingredients.

83. The composition of claim 82, wherein the HDAC inhibitor is valproic acid.

84. The composition of claim 82, wherein the HDAC inhibitor is carbamazepine.

85. The composition of claim 82, wherein the one or more additional active ingredients are selected from the group consisting of an IGF-1R inhibitor, an mTOR inhibitor, and an EGFR inhibitor.

86. The composition of claim 83, where in the hormonal therapy is tamoxifen.

87. The composition of claim 86, wherein the additional ingredient is EGCG or rapamycin.